These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27892666)

  • 21. Mantle cell lymphoma in the orbital and adnexal region.
    Rasmussen P; Sjö LD; Prause JU; Ralfkiaer E; Heegaard S
    Br J Ophthalmol; 2009 Aug; 93(8):1047-51. PubMed ID: 19429588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mantle Cell Lymphoma Relapsing as Disease of Skin, Orbit and CNS: An Extremely Rare Presentation and a Review of Literature.
    Shaikh H; Jani P; Shah R; Bilimoria F; Uchin J; Mewawalla P
    J Hematol; 2018 Jan; 7(1):38-42. PubMed ID: 32300410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
    Lamonica D; Graf DA; Munteanu MC; Czuczman MS
    J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.
    Kang BW; Sohn SK; Moon JH; Chae YS; Kim JG; Lee SJ; Kim WS; Lee JJ; Lee SR; Park KU; Lee HS; Lee WS; Won JH; Park MR; Kwak JY; Kim MK; Kim HJ; Oh SY; Kang HJ; Suh C
    Blood Res; 2014 Mar; 49(1):15-21. PubMed ID: 24724062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinical features, therapeutic effects and prognosis of mantle cell lymphoma].
    Zhang HX; Xu J; Liu T; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):231-5. PubMed ID: 21569704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results from the Belgian mantle cell lymphoma registry.
    Vergote V; Janssens A; André M; Bonnet C; Van Hende V; Van Den Neste E; Van Eygen K; Maerevoet M; Pranger D; Schroyens W; Debussche S; Maertens V; Beel K; Lemmens J; Caron C; Delrieu V; Van Den Broeck I; Vanstraelen G; Jacquy C; Schauvlieghe L; De Samblanx H; Madoe V; Meers S; Boulet D; Verhoef G; Van Hoof A
    Acta Clin Belg; 2017 Jun; 72(3):172-178. PubMed ID: 28222652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCL
    Jerkeman M; Ekberg S; Glimelius I; Albertsson-Lindblad A; Entrop JP; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
    Hemasphere; 2023 Aug; 7(8):e928. PubMed ID: 37529083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
    Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.